Cargando…

HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site

Here we report the construction, antigenicity and initial immunogenicity testing of DNA and modified vaccinia Ankara (MVA) vaccines expressing virus-like particles (VLPs) displaying sequential clade C Envelopes (Envs) that co-evolved with the elicitation of broadly neutralizing antibodies (bnAbs) to...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCurley, Nathanael P., Domi, Arban, Basu, Rahul, Saunders, Kevin O., LaBranche, Celia C., Montefiori, David C., Haynes, Barton F., Robinson, Harriet L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5636061/ https://www.ncbi.nlm.nih.gov/pubmed/29020058 http://dx.doi.org/10.1371/journal.pone.0177863

Ejemplares similares

A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model
por: Brault, Aaron C., et al.
Publicado: (2017)

A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge
por: Salvato, Maria S., et al.
Publicado: (2019)

Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants
por: Martinez, David R., et al.
Publicado: (2020)

A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge
por: Domi, Arban, et al.
Publicado: (2018)

Infant transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired maternal plasma
por: Kumar, Amit, et al.
Publicado: (2018)

Vaccine-elicited systemic and mucosal humoral responses of lactating rhesus monkeys vaccinated with the transmitted/founder HIV Envelope 1086C
por: Fouda, G, et al.
Publicado: (2012)

Priming with DNA encoding functional trimers and boosting with soluble trimeric protein elicited tier 2 neutralizing antibodies in non-human primates
por: Chakrabarti, BK, et al.
Publicado: (2012)

Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticles
por: Brouwer, Philip J. M., et al.
Publicado: (2021)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Retraction: eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2014)

Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine
por: Chamcha, Venkateswarlu, et al.
Publicado: (2016)

A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity
por: Rubio, Adonis A., et al.
Publicado: (2021)

Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges
por: Khattar, Sunil K., et al.
Publicado: (2015)

Monocyte-Derived Dendritic Cells Exhibit Increased Levels of Lysosomal Proteolysis as Compared to Other Human Dendritic Cell Populations
por: McCurley, Nathanael, et al.
Publicado: (2010)

Thermostability of Well-Ordered HIV Spikes Correlates with the Elicitation of Autologous Tier 2 Neutralizing Antibodies
por: Feng, Yu, et al.
Publicado: (2016)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1
por: Wee, Edmund G., et al.
Publicado: (2019)

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1
por: Wee, Edmund G., et al.
Publicado: (2022)

Structure-guided changes at the V2 apex of HIV-1 clade C trimer enhance elicitation of autologous neutralizing and broad V1V2-scaffold antibodies
por: Sahoo, Anusmita, et al.
Publicado: (2022)

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site
por: Crooks, Ema T., et al.
Publicado: (2015)

Identification of a clade A HIV envelope immunogen from Protocol G that elicits neutralizing antibodies to tier 2 viruses
por: Hoffenberg, S, et al.
Publicado: (2012)

Immunization with an SIV-based IDLV Expressing HIV-1 Env 1086 Clade C Elicits Durable Humoral and Cellular Responses in Rhesus Macaques
por: Negri, Donatella, et al.
Publicado: (2016)

Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches
por: Pauthner, Matthias, et al.
Publicado: (2017)

Immune Related Genes Underpin the Evolution of Adaptive Immunity in Jawless Vertebrates
por: McCurley, Nathanael, et al.
Publicado: (2012)

Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome
por: Song, Hongshuo, et al.
Publicado: (2012)

Oligomannose Glycopeptide Conjugates Elicit Antibodies Targeting the Glycan Core Rather than Its Extremities
por: Nguyen, Dung N., et al.
Publicado: (2019)

Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies
por: Bale, Shridhar, et al.
Publicado: (2018)

Neutralization tiers of HIV-1
por: Montefiori, David C., et al.
Publicado: (2018)

Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus
por: Manoharan, Vinoth K., et al.
Publicado: (2018)

Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction
por: Foster, Toshana L., et al.
Publicado: (2016)

Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein
por: Vassell, Russell, et al.
Publicado: (2015)

The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection
por: Goonetilleke, Nilu, et al.
Publicado: (2009)

Mixed Adjuvant Formulations Reveal a New Combination That Elicit Antibody Response Comparable to Freund's Adjuvants
por: Lai, Rachel P. J., et al.
Publicado: (2012)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

Correction: Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2014)

Breadth and magnitude of antigen-specific antibody responses in the control of plasma viremia in simian immunodeficiency virus infected macaques
por: Pahar, Bapi, et al.
Publicado: (2016)

Polyclonal HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated virus loads in infant rhesus monkeys.
por: Himes, Jonathon E., et al.
Publicado: (2018)

Transmitted/Founder Simian Immunodeficiency Virus Envelope Sequences in Vesicular Stomatitis and Semliki Forest Virus Vector Immunized Rhesus Macaques
por: Gambhira, Ratish, et al.
Publicado: (2014)

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
por: Salazar-Gonzalez, Jesus F., et al.
Publicado: (2009)

Comparison of Neutralizing Antibody Responses Elicited from Highly Diverse Polyvalent Heterotrimeric HIV-1 gp140 Cocktail Immunogens versus a Monovalent Counterpart in Rhesus Macaques
por: Bowles, Emma J., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4jv44881g7ssk7agkvq6qk3662